Table 2.
Predictors of chemotherapy use in women with immature teratoma.
| aRR | ||
|---|---|---|
| Age | ||
| 18–19 | Referent | |
| 20–29 | 1.11 (0.96–1.29) | |
| 30–39 | 1.08 (0.92–1.26) | |
| 40–49 | 0.93 (0.74–1.17) | |
| ≥50 | 0.60 (0.40–0.91)* | |
| Race | ||
| White | Referent | |
| Black | 1.03 (0.91–1.17) | |
| Hispanic | 1.03 (0.90–1.18) | |
| Other | 1.15 (0.96–1.38) | |
| Unknown | 1.15 (0.89–1.48) | |
| Insurance status | ||
| Private | Referent | |
| Medicare | 1.06 (0.70–1.59) | |
| Medicaid | 1.11 (0.99–1.24) | |
| Other Government | 1.10 (0.86–1.41) | |
| Uninsured | 1.10 (0.95–1.28) | |
| Unknown | 0.81 (0.51–1.28) | |
| Income | ||
| <$30,000 | Referent | |
| $30,000–$34,999 | 0.98 (0.84–1.14) | |
| $35,000–$45,999 | 1.03 (0.89–1.18) | |
| $46,000+ | 0.97 (0.83–1.13) | |
| Unknown | 1.07 (0.80–1.44) | |
| Facility type | ||
| Community cancer | Referent | |
| Academic/research | 1.39 (1.08–1.79)* | |
| Comprehensive community cancer | 1.30 (1.01–1.67)* | |
| Other | 1.55 (1.04–2.28)* | |
| Facility region | ||
| Eastern | Referent | |
| Midwest | 0.91 (0.79–1.05) | |
| South | 1.04 (0.91–1.19) | |
| West | 0.90 (0.78–1.05) | |
| Facility location | ||
| Metropolitan | Referent | |
| Urban | 0.98 (0.86–1.13) | |
| Rural | 1.19 (0.94–1.49) | |
| Unknown | 0.97 (0.73–1.30) | |
| Year of diagnosis | ||
| 1998 | Referent | |
| 1999 | 1.07 (0.80–1.45) | |
| 2000 | 1.15 (0.82–1.61) | |
| 2001 | 1.01 (0.72–1.41) | |
| 2002 | 1.00 (0.73–1.36) | |
| 2003 | 1.02 (0.76–1.38) | |
| 2004 | 1.07 (0.79–1.43) | |
| 2005 | 0.95 (0.70–1.29) | |
| 2006 | 1.04 (0.78–1.38) | |
| 2007 | 1.15 (0.88–1.52) | |
| 2008 | 0.94 (0.70–1.24) | |
| 2009 | 0.94 (0.70–1.25) | |
| 2010 | 0.97 (0.73–1.30) | |
| 2011 | 0.80 (0.58–1.09) | |
| 2012 | 0.96 (0.71–1.30) | |
| Stage | ||
| IA | Referent | |
| IB–IC | 1.40 (1.22–1.61)* | |
| INOS | 0.98 (0.78–1.23) | |
| II | 1.62 (1.39–1.90)* | |
| III | 1.53 (1.36–1.71)* | |
| IV | 1.51 (1.20–1.88)* | |
| Unknown | 0.97 (0.80–1.18) | |
| Grade | ||
| Well | Referent | |
| Moderate | 3.52 (2.62–4.73)* | |
| Poorly | 3.98 (2.99–5.30)* | |
| Unknown | 2.57 (1.89–3.48)* | |
aRR: Adjusted risk ratio (95% confidence interval).
46 patients with unknown chemotherapy were excluded. Age, race, insurance status, income, facility type, region, location, year of diagnosis, stage and grade were included in the generalized estimating equations accounting for facility-level clustering.
*
P<0.05.